Details of the Drug Combinations

General Information of This Drug (ID: DMCGATN)

Drug Name

Apabetalone DMCGATN

Synonyms

RVX 000222; 1044870-39-4; 2-(4-(2-Hydroxyethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one; RVX-000222; 2-[4-(2-Hydroxyethoxy)-3,5-Dimethylphenyl]-5,7-Dimethoxyquinazolin-4(3h)-One; UNII-8R4A7GDZ1D; RVX 000222; 8R4A7GDZ1D; QC-216; AK110565; Apabetalone [INN]; RVX000222; Apabetalone [USAN:INN]; 1K0; 4mr4; 4mr6; 4j1p; 4j3i; Apabetalone (USAN/INN); D0N7WW; SCHEMBL145019; GTPL7034; SCHEMBL17002023; AOB2133; DTXSID90146502; MolPort-027-835-445; NETXMUIMUZJUTB-UHFFFAOYSA-N; HMS3653C10; EX-A1110; BCP07787; ZINC4319

Indication

Disease Entry	ICD 11	Status	REF
Cardiac events	MC82	Phase 3	[1]
Cardiovascular disease	BA00-BE2Z	Phase 3	[2]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Investigative	[3]
------------------------------------------------------------------------------------

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

3 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Apabetalone + Rosuvastatin	DC8KRUV	Rosuvastatin	Dyslipidemia	[4]
Atorvastatin + Apabetalone	DC9O47U	Atorvastatin	Dyslipidemia	[4]
Atorvastatin + Apabetalone	DC6TP5I	Atorvastatin	Diabetes Mellitus, Type 2	[5]
------------------------------------------------------------------------------------

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	Small molecules, big targets: drug discovery faces the protein-protein interaction challenge.Nat Rev Drug Discov. 2016 Aug;15(8):533-50.
3	Resverlogix Clinical Candidate Apabetalone Featured as a Potential COVID-19 Treatment in Recent PublicationEpigenetic BET-inhibition to combat COVID-19. Mar 24, 2020.
4	ClinicalTrials.gov (NCT01863225) Characterization of Multi-dose RVX000222 in Combination With Statin Treatment in Dyslipidemia
5	ClinicalTrials.gov (NCT02586155) Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD